We therefore conducted a comprehensive assessment of PIK3CA mutation status and gene signatures (GSs) of PI3K pathway activity in tumours from patients with ER + primary BC in a clinical trial of the aromatase inhibitor anastrozole and related these to the drug’s antiproliferative effects and other key biomarkers of prognosis in ER + disease. The gene discussed is ESR1; the disease is breast cancer.